Nantkwest Inc (NASDAQ:NK) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.56 and last traded at $1.57, with a volume of 1932 shares. The stock had previously closed at $1.67.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Wednesday, October 10th. Citigroup decreased their target price on shares of Nantkwest to $3.00 in a research report on Sunday, December 2nd. BidaskClub raised shares of Nantkwest from a “sell” rating to a “hold” rating in a research report on Sunday, September 2nd. Jefferies Financial Group reaffirmed a “hold” rating and set a $3.50 price target on shares of Nantkwest in a research report on Thursday, November 15th. Finally, ValuEngine raised shares of Nantkwest from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $3.58.
The stock has a market cap of $123.59 million, a price-to-earnings ratio of -1.28 and a beta of 3.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.31 and a current ratio of 3.31.
In other Nantkwest news, Director Steve Gorlin sold 47,050 shares of Nantkwest stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $2.43, for a total transaction of $114,331.50. Following the transaction, the director now directly owns 149,230 shares of the company’s stock, valued at $362,628.90. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 469,251 shares of company stock worth $919,880. 72.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Nantkwest by 132.8% during the third quarter. JPMorgan Chase & Co. now owns 111,641 shares of the biotechnology company’s stock valued at $413,000 after purchasing an additional 63,689 shares during the period. Millennium Management LLC raised its stake in shares of Nantkwest by 402.4% during the first quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock valued at $610,000 after purchasing an additional 125,544 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Nantkwest by 40.5% during the second quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock valued at $521,000 after purchasing an additional 49,040 shares during the period. Bridgeway Capital Management Inc. raised its stake in shares of Nantkwest by 75.0% during the third quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 75,000 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Nantkwest by 144.2% during the second quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 127,694 shares during the period. Institutional investors own 13.55% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Nantkwest (NK) Hits New 12-Month Low at $1.56” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2018/12/08/nantkwest-nk-hits-new-12-month-low-at-1-56.html.
About Nantkwest (NASDAQ:NK)
NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Further Reading: Growth Stocks
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.